Nebraska
Requires Coverage of Comprehensive Biomarker Testing
Only For Some Plans
Highlighted Disparity
No racial disparities were found in Nebraska for these lung cancer metrics
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases in Nebraska is 51.9 and not significantly different than the national rate of 52.8.
- Nebraska ranks 19th among all states, placing it in the average tier.
- Over the last five years, the rate of new cases in Nebraska improved by 10%.
- In 2022, the most recent year of data available for this report, the COVID-19 pandemic continued to disrupt access to medical care, including delays and reductions in cancer diagnoses and screening. This led to a decline in incidence rates for most cancers, including lung cancer, and should not be interpreted as a reduction in the underlying cancer burden.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer in Nebraska is 30.0%, which is not significantly different than the national rate of 29.7%.
- Nebraska ranks 19th among the 39 states with survival data, placing it in the average tier.
- Over the last five years, the survival rate in Nebraska improved by 34%.
Early Diagnosis:
- In Nebraska, 31.3% of cases are caught at an early stage, which is significantly higher than the national rate of 28.1%.
- Nebraska ranks 8th among the 50 states with data on early-stage diagnosis, placing it in the above average tier.
- Over the last five years, the early diagnosis rate in Nebraska improved by 27%.
Lung Cancer Treatment
Biomarker Coverage:
- Nebraska required some insurance plans to cover comprehensive biomarker testing, including for lung cancer, as of August 2025.
Surgical Treatment:
- Nebraska ranked 19th (out of 49 states with available data) with 20.9% of cases undergoing surgery as part of the first course of treatment, which is not significantly different than the national rate of 20.7%.
- This places Nebraska in the average tier.
- Over the last five years, the percent of cases undergoing surgery in Nebraska did not change significantly.
No Treatment:
- Nebraska ranked 19th (out of 49 states with available data) with 19.0% of cases not receiving any treatment, which is significantly lower than the national rate of 21.0%.
- This places Nebraska in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in Nebraska improved by 26%.
Screening
Screening for High Risk:
- In Nebraska, 23.6% of those at high risk were screened, which was not significantly different than the national rate of 18.2%.
- It ranks 8th among all states, placing it in the above average tier.
- Screening rates in this year’s report have been updated to correct an error in the data source and should not be compared to previous reports.
Prevention
Tobacco Use:
- The 2023 smoking rate in Nebraska is 12.1% and not significantly different than the national rate of 11.4%.
- It ranks 25th among all states, placing it in the average tier.
Radon Exposure:
- In Nebraska, 55.8% of radon test results were at or above the action level recommended by EPA.
- It ranks 48th among all states, placing it in the bottom tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 62.2 per 100,000 population among Black individuals in Nebraska, not significantly different than the rate of 54.2 among Black individuals nationally, and not significantly different than the rate of 52.5 among white individuals in Nebraska.
- The five-year survival rate is 29.3% among Black individuals in Nebraska, not significantly different than the rate of 27.1% among Black individuals nationally, and not significantly different than the rate of 29.9% among white individuals in Nebraska.
- 30.5% of lung cancer cases are diagnosed at an early stage among Black individuals in Nebraska, not significantly different than the rate of 25.1% among Black individuals nationally, and not significantly different than the rate of 31.4% among white individuals in Nebraska.
- 15.5% of Black individuals with lung cancer in Nebraska underwent surgery, not significantly different than the rate of 17.1% among Black individuals nationally, and not significantly different than the rate of 21.2% among white individuals in Nebraska.
- 19.2% of Black individuals with lung cancer in Nebraska did not receive any treatment, not significantly different than the rate of 22.7% among Black individuals nationally, and not significantly different than the rate of 18.8% among white individuals in Nebraska.
Latino individuals:
- The rate of new lung cancer cases is 31.8 per 100,000 population among Latino individuals in Nebraska, not significantly different than the rate of 27.9 among Latino individuals nationally, and significantly lower than the rate of 52.5 among white individuals in Nebraska.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- 29.2% of lung cancer cases are diagnosed at an early stage among Latino individuals in Nebraska, not significantly different than the rate of 23.9% among Latino individuals nationally, and not significantly different than the rate of 31.4% among white individuals in Nebraska.
- 20.8% of Latino individuals with lung cancer in Nebraska underwent surgery, not significantly different than the rate of 21.4% among Latino individuals nationally, and not significantly different than the rate of 21.2% among white individuals in Nebraska.
- 24.0% of Latino individuals with lung cancer in Nebraska did not receive any treatment, not significantly different than the rate of 25.8% among Latino individuals nationally, and not significantly different than the rate of 18.8% among white individuals in Nebraska.
Asian or Pacific Islander individuals:
- The rate of new lung cancer cases is 40.8 per 100,000 population among Asian or Pacific Islanders individuals in Nebraska, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and not significantly different than the rate of 52.5 among white individuals in Nebraska.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
30.3% of lung cancer cases are diagnosed at an early stage among Asian or Pacific Islander individuals in Nebraska, not significantly different than the rate of 23.7% among Asian or Pacific Islander individuals nationally, and not significantly different than the rate of 31.4% among white individuals in Nebraska.
- Other lung cancer rates are not available for Asian or Pacific Islander individuals in Nebraska due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- The rate of new lung cancer cases is 61.0 per 100,000 population among Indigenous peoples (American Indians/Alaska Natives) in Nebraska, not significantly different than the rate of 39.8 among Indigenous Peoples nationally, and not significantly different than the rate of 52.5 among white individuals in Nebraska.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Nebraska due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Nebraska falling into the above average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Nebraska required some insurance plans to cover comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Nebraska falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: October 29, 2025
